Skip to main content
NACFC 2024 Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Livestreamed Session
Livestreamed Session
Ticketed Session
Ticketed Session
Recorded Session
Recorded Session
Back

Deepika Polineni, MD MPH

Washington University in St. Louis

Dr. Deepika Polineni is an Associate Professor at Washington University in St. Louis School of Medicine in the Department of Pediatrics, Division of Allergy and Pulmonary Medicine. She received her bachelor of arts and doctor of medicine degrees from the University of Missouri, Kansas City, and master of public health degree with special emphasis in Epidemiology and Biostatistics from Boston University. She completed internship and residency in Internal Medicine at the University of Michigan in Ann Arbor, Michigan, fellowship in Pulmonary Medicine at the University of North Carolina at Chapel Hill, and post-doctoral research in Pulmonary Medicine at Washington University in St. Louis. She undertook her training in studies of cystic fibrosis translational research at the UNC-Chapel Hill Cystic Fibrosis Pulmonary Research and Treatment Center and concurrently served as the Human Research Protections Officer for the United States Environmental Protection Agency. Dr. Polineni studies genetic modifiers of lung disease severity in people with CF to identify novel treatment targets. Her research focus has been integrating the findings of CF genomic, nasal epithelial transcriptomic and airway metabolomic studies conducted to identify differential gene expression and metabolite variability associated with CF lung disease severity to identify novel pathways that may serve to therapeutically benefit people with CF. In doing so, recent studies from her laboratory have focused on the effects of methylthioadenosine in airway epithelia. She has also led the development of biorepositories aimed toward identifying biomarkers predictive of treatment response to newer CFTR modulators. Dr. Polineni has served as a national and global principle investigator in two Phase 3 studies of CFTR modulator therapies. She is a member of the CFF Therapeutic Development Network Protocol Review Committee, and a member of the CFF Genetic Therapies Working Group.

Presentation(s):